Evaluation of the reintroducing FOLFOX or XELOX +/- BV in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy.(REACT study)
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000006523
- Lead Sponsor
- Hyogo College of Medicine, Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Not provided
1)Blood transfusion, administration of hematopoietic factor (human blood products or G-CSF, etc). 2)Serious drug allergy. 3)Peripheral sensory neuropathy >= Grade 2. 4)Active synchronous malignancies. 5)Massive pleural or pericardial effusion ,or ascites. 6)Infection of clinical issue or fever suspicious of infection. 7)Brain metastasis. 8)Cardiac disease complications (congested heart failure, symptomatic coronary artery disease, uncontrollable cardiac dysrhythmia or history of myocardial infarction within 12 months, etc). 9)Lung disease of clinical issue. 10)Bleeding that requires medication or transfusion. 11)Uncontrolled diarrhea. 12)Ileus or bowel obstruction. 13)Clinically significant mental or psychological disease. 14)Insulin-treated diabetic patients. 15)Women who are pregnant or breast-feeding. 16)Other patients who are unfit for the study as determined by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate disease control rate
- Secondary Outcome Measures
Name Time Method safety progression free survival time to treatment failure overall survival relative dose intensity